Could a common diabetes pill help people with rare lung disease breathe easier?
NCT ID NCT05179356
First seen Jan 29, 2026 · Last updated May 25, 2026 · Updated 13 times
Summary
This study tested the drug dapagliflozin, usually used for diabetes, in 52 adults with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension. The goal was to see if it could improve exercise capacity and heart function. Participants took the drug or a placebo for a period, and changes in their peak oxygen use during exercise (VO2 max) and other heart measures were tracked.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Rigshospitalet
Copenhagen, 2100, Denmark
Conditions
Explore the condition pages connected to this study.